What Bioxyne does

Bioxyne Ltd (ASX: BXN) is an Australian publicly-listed pharmaceutical manufacturing and distribution group operating through its wholly-owned subsidiary Breathe Life Sciences (BLS) and the BLS Pharma parent brand. The group holds a TGA GMP-licensed manufacturing facility in Brisbane and is the first and only entity in Australia to have received a GMP manufacturing license for MDMA and Psilocybin (February 2024). Bioxyne's core business is contract drug manufacturing, sponsorship, import/export, and wholesale distribution of investigational and psychotropic medicines, including medicinal cannabis, MDMA, and psilocybin products, with manufacturing capabilities spanning Schedule 3, 4, and 8 medicines. Its clients include licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors, served across Australasia, the UK, Germany, the EU, Japan, and the USA.

Bioxyne generates revenue through multiple streams: contract pharmaceutical manufacturing under GMP, wholesale distribution of controlled substances (via BLS Wholesalers), exclusive supply agreements with international partners (such as the AU$50 million ADREXpharma deal for the German market and a manufacturing partnership with Aurora Cannabis covering sublingual oils and vape products), and direct-to-consumer sales of own-brand health products under the Dr Watson® and PCC® brands via e-commerce and Amazon. The company reports 3,000,000+ medicines manufactured annually across 200+ brands distributed to 10+ countries, with Breathe Life Sciences having scaled from AU$8 million annual turnover to AU$8 million per month in revenue.

The group is structured into three primary commercial entities: Breathe Life Sciences (pharmaceutical manufacturing and wholesale), BLS Wholesalers (Australian licensed importer/manufacturer/wholesaler), and Dr Watson® (consumer health brand covering CBD, NADs, and functional mushrooms). Leadership is anchored by founder and managing director Samuel Watson. The strategic positioning is a regulatory-first contract manufacturer leveraging Australia's unique TGA pathway for psychedelic medicines to serve both domestic special access prescribers and international pharmaceutical sponsors, with management's stated goal of becoming a billion-dollar company within five years.

Name

Bioxyne

Legal name

Bioxyne Ltd

Website

https://bioxyne.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Bioxyne is an Australian publicly-listed pharmaceutical manufacturer and distributor operating through Breathe Life Sciences, holding Australia's first GMP license for MDMA and psilocybin. It contract-manufactures and distributes medicinal cannabis, MDMA, and psilocybin products to licensed clinics, pharmacies, and international pharmaceutical partners across 10+ countries.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

akta.pro secondary industries

Biologics & Biosimilars Distributors (HLAIAJAH), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• GMP pharmaceutical manufacturing
• Medicinal cannabis manufacturing
• Investigational medicines distribution
• Contract drug manufacturing
• Consumer health supplements

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Pharmaceutical Manufacturing (GMP): Contract drug manufacturing services for clients including licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. Services include wholesale and distribution of medicinal cannabis, MDMA, and psilocybin products.
2. Medicinal Cannabis Supply Agreements: Supply deals for medicinal cannabis products including the AU$50 million two-year supply agreement with ADREXpharma for the German market.
3. Own-Brand Products (Dr Watson, PCC): Direct-to-consumer and retail distribution of own-brand prescription medicines and health products including Dr Watson CBD products, NADs, and food grade mushrooms.
4. Wholesale Distribution Services: Wholesale distribution services for medicinal cannabis and controlled substances in Australia, Europe, UK, Japan, and USA through BLS Wholesalers and Breathe Life Sciences.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

Bioxyne, through its BLS Pharma and Breathe Life Sciences subsidiaries, is a contract drug manufacturer, sponsor, importer, exporter, and wholesale distributor of investigational medicines including medicinal cannabis, MDMA, and psilocybin products. It also produces and distributes own-brand consumer health products (Dr Watson, PCC) such as CBD, nootropics, functional mushrooms, NADs, and skincare via direct e-commerce and Amazon.

Product overview

BLS Pharma/Bioxyne operates a multi-brand pharmaceutical and life sciences platform consisting of the BLS (Breathe Life Sciences) manufacturing and wholesale subsidiary, Dr Watson® direct-to-consumer brand, and BLS Wholesalers. The core BLS subsidiary provides GMP-certified contract pharmaceutical manufacturing for cannabis, MDMA, and psilocybin products across Australia, Europe, and the UK. The Dr Watson® brand serves consumers with CBD supplements, nootropics, functional mushrooms, and skincare, while the PCC® brand represents legacy consumer health products. The group offers end-to-end services including R&D, manufacturing, quality control, import/export, and international distribution of investigational medicines and consumer health products.

Differentiator

Problem solved

Functional benefit

Brands

• Dr Watson: Internationally trademarked direct-to-consumer brand featuring supplements, nootropics, functional mushrooms, and skincare. Approved by Amazon for CBD products. Operates in UK, EU, Japan, and USA.
• BLS Wholesalers

Products and services

• GMP Contract Pharmaceutical Manufacturing Contract drug manufacturing, sponsor, import, export, and wholesale distribution services for investigational and psychotropic medicines (cannabis, MDMA, psilocybin) delivered under TGA GMP licence for licensed clinics, pharmacies, wholesale distributors, cultivators, API manufacturers, and pharmaceutical brand sponsors.
• GMP Psilocybin Capsules GMP-manufactured psilocybin capsules commercialised for the Australian market for investigational treatment of mental health disorders.
• BLS Wholesalers Distribution Services Licensed wholesale distribution of Schedule 3, 4, and 8 medicines (medicinal cannabis and controlled substances) to pharmacies, manufacturers, and patients nationwide in Australia.
• Dr Watson Consumer Health Brand Internationally trademarked direct-to-consumer brand featuring CBD products, NADs, functional mushrooms, nootropics, and skincare, distributed via direct e-commerce and Amazon in UK, EU, Japan, USA, and Australasia.

Quantifiable outcome

• Scaled from $8M annual turnover to $8M monthly revenue
• +2 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• ADREXpharma GmbHcoreChannel Partner/ Reseller/ Distributor · 1 May 2026AU$50 million exclusive medicinal cannabis supply agreement with German pharmaceutical company ADREXpharma. Two-year contract facilitating Bioxyne's entry into the German medicinal cannabis market, with AU$25 million minimum guaranteed in first year. Deal significantly boosts European revenue visibility.
• Aurora Cannabis Inc.coreStrategic or Co-development Partner · 1 April 2026Manufacturing agreement with global cannabis leader Aurora Cannabis Inc. covering GMP-certified medicinal cannabis oils for Australian market with first deliveries completed. Expansion planned into GMP-manufactured cannabis vapes for Australia, UK, and Germany. Deal provides third-party validation of Bioxyne's GMP manufacturing capabilities and entry into Aurora's global supply chain. Products include over 5,000 sublingual oil products and 20,000 vape units.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Aurora Cannabis Inc. NASDAQ/TSX-listed large global cannabis operator. Functions both as a Bioxyne customer (manufacturing agreement) and a broader incumbent shaping the global medicinal cannabis supply chain that Bioxyne contracts into.

Direct peers

• MediPharm Labs Corp: TSX-listed (LABS) pure-play cannabis contract manufacturer with GMP-certified facilities. Highly analogous business model to BLS - contract GMP manufacturing and wholesale of cannabinoid APIs/products - making it one of the closest comparable contract manufacturers globally.
• Cann Group Limited: ASX-listed Australian medicinal cannabis cultivator and manufacturer with TGA GMP-licensed facilities. Closest direct Australian comparison: same regulatory licensing environment, same customer base of clinics/pharmacies, overlapping Schedule 4/8 medicine focus.
• Clever Leaves Holdings Inc. NASDAQ-listed (CLVR) Colombian-based GMP-certified cannabis cultivator and B2B manufacturer. Comparable contract-manufacturing and white-label distribution model serving international cannabis brands, similar to BLS's relationship with Aurora Cannabis.
• Althea Group Holdings: ASX-listed (AGH) Australian medicinal cannabis company covering cultivation, manufacturing, wholesale distribution, and education to clinicians. Operates in the same TGA-licensed ecosystem and targets identical pharmacy/clinic customers.
• Vitura Health Limited: ASX-listed (VIT, formerly Cronos Australia) Australian medicinal cannabis distribution and consumer health company. Direct peer operating in identical pharmacy/clinic distribution channels and competing for the same prescriber relationships across Australia.
• Mind Medicine (MindMed) Inc. NASDAQ/NEO-listed (MNMD) psychedelic medicine developer focused on MDMA, LSD and psilocybin for mental health. Direct peer to Bioxyne's GMP MDMA/psilocybin manufacturing capability on the supply side of the same psychedelic ecosystem.
• Bod Science Limited: ASX-listed (BOD) Australian medicinal cannabis and CBD consumer health company. Direct competitor in Australian pharmacy/clinic distribution and overlapping D2C CBD product lines with Bioxyne's Dr Watson brand.
• Compass Pathways plc: NASDAQ-listed (CMPS) developer of psilocybin therapy for treatment-resistant depression. A direct peer in the same psychedelic medicine category Bioxyne manufactures for, sharing the mental-health indication focus and regulatory pathway timeline.

Regional players

• Oxford Cannabinoid Technologies Holdings plc: LSE-listed (OCTP) UK-based cannabinoid drug development company. Operates in the same UK medicinal cannabis regulation environment as Bioxyne's Breathe Life Sciences UK entity and pursues overlapping novel cannabinoid therapeutics for pain indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Bioxyne

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioxyne